Status:
COMPLETED
Adjuvant Capecitabine in Elderly Patients With Breast Cancer: a Phase II Study
Lead Sponsor:
Jules Bordet Institute
Conditions:
Elderly Patients
Breast Cancer
Eligibility:
FEMALE
70+ years
Phase:
PHASE2
Brief Summary
Determination of guidelines regarding the use of adjuvant chemotherapy for early breast cancer in this population of Patients over 70 years old.
Detailed Description
Patients over 70 years old are under represented in clinical trials and there are no clear guidelines regarding the use of adjuvant chemotherapy for early breast cancer in this population. Whether CT ...
Eligibility Criteria
Inclusion
- Women aged ³70 years
- Histologic diagnosis of early breast cancer for which the treating physician considers adjuvant chemotherapy to be beneficial. Recommended situations are for example:
- endocrine non responsive (ER- and PgR -) and pT\>1 cm, any T if N+ OR
- endocrine responsiveness doubtful (ER and/or PgR- or poor \[3 to-5 according to Harvey score (12) or £ 30% of positive cells by immunohistochemistry) and other risk factors (pT³2 cm or N+ or G3 or Her-2/neu positive, etc.) OR
- endocrine responsive (ER and PgR \> 5 according to Harvey score or \> 30% of positive cells by immunohistochemistry) and at least two risk factors (pT³ 2 cm, N+, G3, Her-2/neu positive, etc.) OR
- Very high risk (N\>3) any ER/PgR.
- ECOG Performance status £ 1
- No previous exposition to chemotherapy in the neoadjuvant setting
- Adequate organ function including:
- neutrophils ³ 1.5 x 109 /l
- platelets ³100 x 109 / l
- bilirubin \< 1.25 x upper normal limit for the institution
- transaminases \< 2.5 x upper normal limit for the institution
- calculated creatinine clearance of \> 30ml/min (using the Crockoft and Gault formula)
- absence of
- symptomatic ventricular arrhythmias;
- clinically significant Congestive Heart Failure;
- clinical and/or ECG evidence of myocardial infarction within the last 12 months;
- Coronary artery disease requiring medication.
- Absence of any psychological, familial or sociological condition or comorbidities that may affect compliance
- Written informed consent obtained according to local ethics committee guidelines -
Exclusion
- N/A-
Key Trial Info
Start Date :
January 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2009
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT00263705
Start Date
January 1 2003
End Date
August 1 2009
Last Update
February 24 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jules Bordet Institute
Brussels, Belgium, 1000